Cabiralizumab

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb) . Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA) . Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research[1][2][3][4].

Product Specifications

CAS Number

[1613144-80-1]

Product Name Alternative

FPA 008; Anti-Human CSF1R Recombinant Antibody

UNSPSC

12352203

Target

C-Fms

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cabiralizumab.html

Purity

99.73

Solubility

10 mM in DMSO

Smiles

[Cabiralizumab]

Molecular Weight

(146.02 kDa)

References & Citations

[1]Weiss SA, et al. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27 (17) :4757-4767. |[2]Peyraud F, et al. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19 (11) :70. |[3]Djureinovic D, et al. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Mol Cancer. 2023 Nov 14;22 (1) :182.|[4]Arnoletti JP, et al. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation. PLoS One. 2022 Mar 22;17 (3) :e0265725.